Haemacure to Present at the 11th Annual BIO CEO & Investor Conference



    TSX: HAE

    MONTREAL, Feb. 3 /CNW Telbec/ - Haemacure Corporation (TSX: HAE)
announced today that Joseph Galli, Chairman and Chief Executive Officer of
Haemacure will present at the BIO CEO & Investor Conference, being held
February 9-10 at the Waldorf-Astoria in New York City. Mr. Galli will present
a corporate progress report, including an update on the Company's lead product
candidate, Hemaseel(R)HMN (fibrin sealant). The Haemacure presentation is
scheduled to begin at 10 AM local time on Monday, February 9th.
    The Haemacure presentation will be webcast live and may be accessed by
clicking on the following link:
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=HAE.TO&item_id=208643
3. The presentation will also be available on the Haemacure website
www.haemacure.com for a limited time following the conference.
    Additional Information on the BIO CEO & Investor Conference is available
at: http://www.ceo.bio.org.

    About Haemacure

    Haemacure Corporation is a specialty biotherapeutics company developing
high-value human plasma-derived protein products for commercialization.
Haemacure's research and development effort is driven by its proprietary
plasma protein extraction technology to develop next-generation products,
including surgical hemostats. Haemacure's lead product candidate,
Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III
clinical trials mid-2009. Haemacure's second product candidate is thrombin, a
component of its fibrin sealant, now in preclinical stage. Follow-on
development will focus on the use of its fibrin sealant in adhesion
prevention, aesthetics, combination with biomaterials, drug delivery,
regenerative medicine, skin graft fixation for burn injuries and wound
management. Haemacure has discovered eleven additional specialty proteins and
enzymes in one if its two plasma fractions and seeks to advance these proteins
and enzymes through partnerships with pharmaceutical and biotechnology
companies. Haemacure is headquartered in Montreal, Quebec and operates offices
in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is
traded under stock symbol HAE on the TSX.

    Forward-looking Statements

    Certain of the statements contained in this news release are
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown. Some examples of known risks are: the impact
of general economic conditions, general conditions in the biotech industry,
changes in the regulatory environment in the jurisdictions in which Haemacure
does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation or otherwise. Consequently,
actual future results may differ materially from the anticipated results
expressed in the forward-looking statements. Haemacure disclaims any intention
or obligation to update these statements.




For further information:

For further information: Haemacure Corporation: Joseph Galli, Chairman
and CEO, (514) 990-7074, jgalli@haemacure.ca; Gilles Lemieux, Secretary, (514)
282-3350 ext. 22, ir@haemacure.ca; Jason Tuthill, Investor Relations, (914)
980-4776, jtuthill@haemacurecorp.com; www.haemacure.com

Organization Profile

HAEMACURE CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890